Allergy Therapeutics saw its stock down by 40% in early trading in London Monday morning after its birch pollen drug failed to move the needle in a key phase 3 trial, though the biotech, no stranger to setbacks, has vowed to keep calm and carry on. The late-stage test saw its experimental drug, known as B301, fail to show a statistically significant difference between active and placebo arms in the primary endpoint of a combined symptom medication score averaged over the peak birch pollen season. Source: Fierce Biotech 18/3/2019